We then performed in-situ hybridization (ISH) of LINC00152 in our own cohort of endocrine therapy-treated ER+ breast cancer patients and demonstrated that higher LINC00152 levels are associated with significantly worse disease-free survival (Fig. 1G, H). Here, CYTOR is linked to breast carcinoma.